Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

6(85.7%)

Phase 1

1(14.3%)

7Total

N/A(6)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT02735291Not ApplicableUnknown

Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia

Role: lead

NCT03488160Not ApplicableUnknown

CAR-T Treatment for Relapse / Refractory Type Safety and Effectiveness of Lymphoma

Role: lead

NCT02725125Not ApplicableUnknown

Study Evaluating the Efficacy and Safety With CAR-T for Stomach Cancer

Role: lead

NCT02728882Not ApplicableUnknown

Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma

Role: lead

NCT03086954Phase 1Unknown

Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive Lymphoma

Role: lead

NCT02729493Not ApplicableUnknown

Study Evaluating the Efficacy and Safety With CAR-T for Liver Cancer

Role: lead

NCT02919046Not ApplicableUnknown

Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma in Children

Role: lead

All 7 trials loaded